litlas
Log inCreate account

Se‐Hoon Lee

Active 2004–2026

Also published as
Se-Hoon Lee
219
Papers
25,027
Citations
86
h-index
201
i10-index

Citations

Citations per year for Se‐Hoon Lee2000: 3 citations2004: 3 citations2005: 13 citations2006: 10 citations2007: 12 citations2008: 22 citations2009: 24 citations2010: 23 citations2011: 53 citations2012: 48 citations2013: 105 citations2014: 96 citations2015: 136 citations2016: 152 citations2017: 203 citations2018: 209 citations2019: 697 citations2020: 916 citations2021: 1,115 citations2022: 1,077 citations2023: 952 citations2024: 1,768 citations2025: 1,243 citations2026: 35 citations2001–2003: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,878 citing papers, 21.3% of this breakdownChina: 2,637 citing papers, 19.5% of this breakdownItaly: 703 citing papers, 5.2% of this breakdownUnited Kingdom: 653 citing papers, 4.8% of this breakdownSouth Korea: 613 citing papers, 4.5% of this breakdownJapan: 605 citing papers, 4.5% of this breakdownFrance: 532 citing papers, 3.9% of this breakdownGermany: 523 citing papers, 3.9% of this breakdownSpain: 421 citing papers, 3.1% of this breakdownCanada: 372 citing papers, 2.8% of this breakdownNetherlands: 311 citing papers, 2.3% of this breakdownSwitzerland: 258 citing papers, 1.9% of this breakdown
0%21.3%Other 22.3%

Institutions

Fields

  • Medicine72.4%
  • Biochemistry, Genetics and Molecular Biology18.5%
  • Immunology and Microbiology5.4%
  • Computer Science1.1%
  • Environmental Science0.6%
  • Engineering0.5%
  • Other1.5%

Topics

  • Cancer Immunotherapy and Biomarkers11.7%
  • Lung Cancer Treatments and Mutations9%
  • Lung Cancer Research Studies5.2%
  • Cancer Genomics and Diagnostics4%
  • Lung Cancer Diagnosis and Treatment3.1%
  • Immunotherapy and Immune Responses2.8%
  • Other64.2%

Coauthors

All papers

Open in search
  1. Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

    Authors: Heather A. Wakelee, Moïshe Liberman, Terufumi Kato, Masahiro Tsuboi, Se‐Hoon Lee, Shugeng Gao, Ke‐Neng Chen, Christophe Dooms, Margarita Majem, E. Eigendorff, Gastón Lucas Martinengo, Olivier Bylicki, Delvys Rodríguez‐Abreu, Jamie E. Chaft, Silvia Novello, Jing Yang, Steven M. Keller, Ayman Samkari, Jonathan Spicer - New England Journal of Medicine 2023 cited by 1,030

  2. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma

    Authors: Nayoung Kim, Hong Kwan Kim, Kyungjong Lee, Yourae Hong, Jong Ho Cho, Jung Won Choi, Jung-Il Lee, Yeon‐Lim Suh, Bo Mi Ku, Hye Hyeon Eum, Soyean Choi, Yoon‐La Choi, Je‐Gun Joung, Woong‐Yang Park, Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn, Hae‐Ock Lee - Nature Communications 2020 cited by 1,337

  3. Lung adenocarcinoma promotion by air pollutants

    Authors: William Hill, Emilia L. Lim, Clare E. Weeden, Claudia Lee, Marcellus Augustine, Kezhong Chen, Feng‐Che Kuan, Fabio Marongiu, Edward J. Evans, David A. Moore, Felipe Silva Rodrigues, Oriol Pich, Björn Bakker, Hongui Cha, Renelle Myers, Febe van Maldegem, Jesse Boumelha, Selvaraju Veeriah, Andrew Rowan, Cristina Naceur‐Lombardelli, Takahiro Karasaki, Monica Sivakumar, Swapnanil De, Deborah R. Caswell, A. Nagano, James R. Black, Carlos Martínez‐Ruiz, Min Hyung Ryu, Ryan D. Huff, Shijia Li, Marie-Julie Favé, Alastair Magness, Alejandro Suárez‐Bonnet, Simon L. Priestnall, Margreet Lüchtenborg, Katrina Lavelle, Joanna Pethick, Steven J. Hardy, Fiona E. McRonald, Meng‐Hung Lin, Clara I. Troccoli, Moumita Ghosh, York E. Miller, Daniel T. Merrick, Robert L. Keith, Maise Al Bakir, Chris Bailey, Mark S. Hill, Lao H. Saal, Yilun Chen, Anthony M. George, Christopher Abbosh, Nnennaya Kanu, Se‐Hoon Lee, Nicholas McGranahan, Christine D. Berg, Peter Sasieni, Richard S. Houlston, Clare Turnbull, Stephen Lam, Philip Awadalla, Eva Grönroos, Julian Downward, Tyler Jacks, Christopher Carlsten, Ilaria Malanchi, Allan Hackshaw, Kevin Litchfield, J.F. Lester, Amrita Bajaj, Apostolos Nakas, Azmina Sodha-Ramdeen, Keng Ang, Mohamad Tufail, Mohammed Fiyaz Chowdhry, Molly Scotland, Rebecca Boyles, Sridhar Rathinam, Claire Wilson, Domenic Marrone, Sean Dulloo, Dean A. Fennell, Gurdeep Matharu, Jacqui Shaw, Joan Riley, Lindsay Primrose, Ekaterini Boleti, Heather Cheyne, Mohammed S. Khalil, Shirley Richardson, Tracey Cruickshank, Gillian Price, Keith M. Kerr, Sarah Benafif, Kayleigh Gilbert, Babu Naidu, Akshay J. Patel, Aya Osman, Christer Lacson, Gerald Langman and 226 more - Nature 2023 cited by 790

  4. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition

    Authors: Kevin Litchfield, James L. Reading, Clare Puttick, Krupa Thakkar, Chris Abbosh, Robert B. Bentham, Thomas B.K. Watkins, Rachel Rosenthal, Dhruva Biswas, Andrew Rowan, Emilia L. Lim, Maise Al Bakir, Virginia Turati, José Afonso Guerra‐Assunção, Lucía Conde, Andrew J.S. Furness, Sunil Kumar Saini, Sine Reker Hadrup, Javier Herrero, Se‐Hoon Lee, Peter Van Loo, Tariq Enver, James Larkin, Matthew D. Hellmann, Samra Turajlic, Sergio A. Quezada, Nicholas McGranahan, Charles Swanton - Cell 2021 cited by 908

  5. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

    Authors: Takashi Kojima, Manish A. Shah, Kei Muro, Éric François, Antoine Adenis, Chih‐Hung Hsu, Toshihiko Doi, Toshikazu Moriwaki, Sung‐Bae Kim, Se‐Hoon Lee, Jaafar Bennouna, Ken Kato, Lin Shen, Peter C. Enzinger, Shukui Qin, Paula Ferreira, Jia Chen, Gustavo Girotto, Christelle de la Fouchardière, Hélène Senellart, Raed Moh’d Taiseer Al-Rajabi, Florian Lordick, Ruixue Wang, Shailaja Suryawanshi, Pooja Bhagia, Soonmo Peter Kang, Jean‐Philippe Metges, on behalf of the KEYNOTE-181 Investigators - Journal of Clinical Oncology 2020 cited by 1,176

  6. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

    Authors: Helena A. Yu, Yasushi Goto, Hidetoshi Hayashi, Enriqueta Felip, James Chih‐Hsin Yang, Martin Reck, Kiyotaka Yoh, Se‐Hoon Lee, Luis Paz‐Ares, Benjamin Besse, Paolo Bironzo, Dong‐Wan Kim, Melissa L. Johnson, Yi‐Long Wu, Thomas John, Steven Kao, Toshiyuki Kozuki, Erminia Massarelli, Jyoti D. Patel, Egbert F. Smit, Karen L. Reckamp, Qian Dong, Pomy Shrestha, Pang‐Dian Fan, Parul Patel, Andrea Sporchia, David Sternberg, Dalila Sellami, Pasi A. Jänne - Journal of Clinical Oncology 2023 cited by 225

  7. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load

    Authors: Hyunchul Jung, Hong Sook Kim, Jeong Yeon Kim, Jong‐Mu Sun, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park, Manel Esteller, Se‐Hoon Lee, Jung Kyoon Choi - Nature Communications 2019 cited by 563

  8. Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC

    Authors: Byoung Chul Cho, Shun Lu, Enriqueta Felip, Alexander I. Spira, Nicolas Girard, Jong-Seok Lee, Se-Hoon Lee, Yurii Ostapenko, Pongwut Danchaivijitr, Baogang Liu, Adlinda Alip, Ernesto Korbenfeld, Josiane Mourão Dias, Benjamin Besse, Ki-Hyeong Lee, Hailin Xiong, Soon-Hin How, Ying Cheng, Gee‐Chen Chang, Hiroshige Yoshioka, James Chih‐Hsin Yang, Michael J. Thomas, Danny Nguyen, Sai‐Hong Ignatius Ou, Sanjay Mukhedkar, Kumar Prabhash, M. D’Arcangelo, Jorge Alatorre-Alexander, Juan Carlos Vázquez Limón, Sara Alves, Daniil Stroyakovskiy, Marina Peregudova, Mehmet Alı Nahıt Şendur, Ozan Yazıcı, Raffaele Califano, Vanesa Gutiérrez Calderón, Filippo de Marinis, Antonio Passaro, Sang‐We Kim, Shirish M. Gadgeel, John Xie, Tao Sun, Melissa Martínez, Mariah Ennis, E. Fennema, Mahesh Daksh, Dawn Millington, Isabelle Leconte, Ryota Iwasawa, Patricia Lorenzini, Mahadi Baig, Sujay Shah, Joshua Bauml, S. Martin Shreeve, Seema Sethi, R.E. Knoblauch, Hidetoshi Hayashi - New England Journal of Medicine 2024 cited by 375

  9. Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice

    Authors: Se‐Hoon Lee, Sung‐Yup Cho, Youngmin Yoon, Chang-Ho Park, Jinyoung Sohn, Jin-Ju Jeong, Bu-Nam Jeon, Mongjoo Jang, Choa An, Suro Lee, Yun Yeon Kim, Gihyeon Kim, Sujeong Kim, Yun-Jae Kim, Gwang Bin Lee, Eun Ju Lee, Sang Gyun Kim, Hong Sook Kim, Yeongmin Kim, Hyun Kim, Hyun Suk Yang, Sarang Kim, Seonggon Kim, Hayung Chung, Myeong Hee Moon, Myung Hee Nam, Jee Young Kwon, Sungho Won, Joon-Suk Park, George M. Weinstock, Charles Lee, Kyoung Wan Yoon, Hansoo Park - Nature Microbiology 2021 cited by 317

  10. Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer

    Authors: Sehhoon Park, Chan‐Young Ock, Hyojin Kim, Sérgio Pereira, Seonwook Park, Minuk Ma, Sangjoon Choi, Seokhwi Kim, Seunghwan Shin, Brian Jaehong Aum, Kyunghyun Paeng, Donggeun Yoo, Hongui Cha, Sunyoung Park, Koung Jin Suh, Hyun Ae Jung, Se Hyun Kim, Yu Jung Kim, Jong‐Mu Sun, Jin-Haeng Chung, Jin Seok Ahn, Myung‐Ju Ahn, Jong Seok Lee, Keunchil Park, Sang Yong Song, Yung‐Jue Bang, Yoon‐La Choi, Tony Mok, Se‐Hoon Lee - Journal of Clinical Oncology 2022 cited by 282

  11. Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas

    Authors: Jake June-Koo Lee, Junehawk Lee, Sehui Kim, Soyeon Kim, Jeonghwan Youk, Seongyeol Park, Yohan An, Bhumsuk Keam, Dong‐Wan Kim, Dae Seog Heo, Young Tae Kim, Jin-Soo Kim, Se Hyun Kim, Jong Seok Lee, Se‐Hoon Lee, Keunchil Park, Ja‐Lok Ku, Yoon Kyung Jeon, Doo Hyun Chung, Peter J. Park, Joon Kim, Tae‐Min Kim, Young Seok Ju - Journal of Clinical Oncology 2017 cited by 508

  12. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Rearranged or Translocated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)

    Authors: Sehhoon Park, Tae Min Kim, Ji‐Youn Han, Gyeong‐Won Lee, Byoung Yong Shim, Yun‐Gyoo Lee, Sang‐We Kim, Il Hwan Kim, Suee Lee, Yu Jung Kim, Ji Hyun Park, Sang-Gon Park, Ki Hyeong Lee, Eun Joo Kang, Ju Won Kim, Seong Hoon Shin, Chan‐Young Ock, Byung‐Ho Nam, Jaebong Lee, Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Myung‐Ju Ahn - Journal of Clinical Oncology 2023 cited by 164

  13. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722

    Authors: Tony Mok, Kazuhiko Nakagawa, Keunchil Park, Yuichiro Ohe, Nicolas Girard, Hye Ryun Kim, Yi‐Long Wu, Justin F. Gainor, Se‐Hoon Lee, Chao‐Hua Chiu, Sang‐We Kim, Cheng‐Ta Yang, Chien Liang Wu, Lin Wu, Meng‐Chih Lin, Jens Samol, Kazuya Ichikado, Mengzhao Wang, Xiaoqing Zhang, Judi Sylvester, Sunney Li, Ann Forslund, James Chih‐Hsin Yang - Journal of Clinical Oncology 2024 cited by 153

  14. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

    Authors: Chiun Hsu, Se‐Hoon Lee, Samuel Ejadi, Caroline Even, Roger B. Cohen, Christophe Le Tourneau, Janice M. Mehnert, Alain P. Algazi, Emilie M.J. van Brummelen, Sanatan Saraf, Pradeep Thanigaimani, Jonathan D. Cheng, Aaron R. Hansen - Journal of Clinical Oncology 2017 cited by 471

  15. Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

    Authors: Natasha B. Leighl, Hiroaki Akamatsu, Sun Min Lim, Ying Cheng, Anna Minchom, Melina E. Marmarelis, Rachel E. Sanborn, James Chih‐Hsin Yang, Baogang Liu, Thomas John, Bartomeu Massutí, Alexander I. Spira, Se‐Hoon Lee, Jialei Wang, Juan Li, Caigang Liu, Silvia Novello, Masashi Kondo, Motohiro Tamiya, Ernesto Korbenfeld, Mor Moskovitz, Ji‐Youn Han, Mariam P. Alexander, Rohit Joshi, Enriqueta Felip, Pei Jye Voon, Pongwut Danchaivijitr, Ping‐Chih Hsu, Felipe José Silva Melo Cruz, Thomas Wehler, Laurent Greillier, Encarnação Teixeira, Danny Nguyen, Joshua K. Sabari, Angel Qin, Dariusz M. Kowalski, Mehmet Alı Nahıt Şendur, John Xie, Debopriya Ghosh, Ali Alhadab, Nahor Haddish‐Berhane, Pamela L. Clemens, Patricia Lorenzini, Remy B. Verheijen, Mohamed Gamil, Joshua Bauml, Mahadi Baig, Antonio Passaro, for the PALOMA-3 Investigators, Hiroaki Akamatsu, Mariam P. Alexander, Annalen Bleckmann, Federico Cappuzzo, Ying Cheng, Byoung Chul Cho, Timuçin Çil, Alexis B. Cortot, Pongwut Danchaivijitr, Till‐Oliver Emde, Dilek Erdem, Enriqueta Felip, F. Estevinho, Maria Lurdes Ferreira, Flavio Ferreira da Silva, Maria Campelo, Laurent Greillier, Alastair Greystoke, Ji‐Youn Han, Ping‐Chih Hsu, Jen‐Yu Hung, Mei Ji, Thomas John, Rohit Joshi, Young‐Chul Kim, Masashi Kondo, Ernesto Korbenfeld, Dariusz M. Kowalski, Se‐Hoon Lee, Natasha B. Leighl, Juan Li, Sheng-Hao Lin, Baogang Liu, Caigang Liu, John Seng-Hooi Low, Melina E. Marmarelis, Bartomeu Massutí, Anna R. Minchom, Sara Moore, Mor Moskovitz, Adnan Nagrial, Danny Nguyen, Silvia Novello, Y. Ohe, Mustafa Özgüroğlu, Özgür Özyılkan, Antonio Passaro, Nir Peled, Naiyarat Prasongsook, Angel Qin, Elisa F. Ramos and 22 more - Journal of Clinical Oncology 2024 cited by 114

  16. LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features

    Authors: Tiangen Chang, Yingying Cao, Hannah J. Sfreddo, Saugato Rahman Dhruba, Se‐Hoon Lee, Cristina Valero, Seong‐Keun Yoo, Diego Chowell, Luc G.T. Morris, Eytan Ruppin - Nature Cancer 2024 cited by 110

  17. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

    Authors: Laura Q.M. Chow, Robert I. Haddad, Shilpa Gupta, Amit Mahipal, Ranee Mehra, Makoto Tahara, Raanan Berger, Joseph P. Eder, Barbara Burtness, Se‐Hoon Lee, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Jared Weiss, Ravit Geva, Chia‐Chi Lin, Hyun Cheol Chung, Amy Meister, Marisa Dolled‐Filhart, Kumudu Pathiraja, Jonathan D. Cheng, Tanguy Y. Seiwert - Journal of Clinical Oncology 2016 cited by 859

  18. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Jonathan Spicer, Marina Chiara Garassino, Heather A. Wakelee, Moïshe Liberman, Terufumi Kato, Masahiro Tsuboi, Se‐Hoon Lee, Ke‐Neng Chen, Christophe Dooms, Margarita Majem, E. Eigendorff, Gastón Lucas Martinengo, Olivier Bylicki, Delvys Rodríguez‐Abreu, Jamie E. Chaft, Silvia Novello, Jing Yang, Ashwini Arunachalam, Steven M. Keller, Ayman Samkari, Shugeng Gao, Shugeng Gao, Sergey Afanasyev, Samreen Ahmed, Todd Alekshun, Gustavo Alves, Ian Anderson, Luiz Henrique Araujo, Alexander Arkhipov, Arvind Arora, Jie Bai, Paul Begin, Aleksandr Belonogov, Henri Berard, Radu Berceanu-Ion, Reyes Bernabe Caro, Igor Bondarenko, Reiner Bonnet, Joaquim Bosch Barrera, Carlos Brocca, Maciej Bryl, Alessandra Bulotta, Olivier Bylicki, Antonio Calles Blanco, Enric Carcereny, Leticia Carvalho, Cristina Cebotaru, Jamie Chaft, Veena Charu, Fabio Chaves, Jun Chen, Ke-Neng Chen, Haiquan Chen, Qixun Chen, Kevin Chen, Chi-Lu Chiang, Chao-Hua Chiu, Saulius Cicenas, Elena Ciubotaru, Tudor Ciuleanu, Ioana Ciurescu, Patrick Cobb, Corlia Coetzee, Dearbhaile Collins, Diego Cortinovis, Kimberly Costas, Dan Costin, Eduardo Henrique Cronemberger, Raymund Cuevo, Sinead Cuffe, Pedro Rafael Martins De Marchi, Tadeu de Paiva Junior, Angelo Delmonte, Ingel Demedts, Koenraad Deschepper, Josiane Dias, Christophe Dooms, Boris Duchemann, Carolina Dutra, Herbert Duvivier, Ekkehard Eigendorff, Vinicius Ernani, Martin Faehling, Luiza Faria, Alexander Fedenko, Hiran Fernando, Roberto Ferrara, Vittorio Ferrari, Gene Finley, Peter Fix, Marcos Flores, Samuel Fourie, Fabio Franke, Klaus-Peter Frohling, Muhammad Furqan, Cristian Gal, Robert Galamaga, Doina Ganea, Apar Kishor Ganti, Shugeng Gao and 176 more - The Lancet 2024 cited by 243

  19. The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors

    Authors: Kyung Hwan Kim, Jinhyun Cho, Bo Mi Ku, Jiae Koh, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Jaekyung Cheon, Young Joo Min, Su‐Hyung Park, Keunchil Park, Myung‐Ju Ahn, Eui‐Cheol Shin - Clinical Cancer Research 2019 cited by 212

  20. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial

    Authors: D. Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan W. Goldman, Fedor Moiseenko, Е. А. Филиппова, İrfan Çiçin, Tudor–Eliade Ciuleanu, Nathalie Daaboul, Chunling Liu, Penelope A. Bradbury, Mor Moskovitz, Nuran Katgı, Pascale Tomasini, Alona Zer, Nicolas Girard, Kristof Cuppens, Ji‐Youn Han, Shang‐Yin Wu, Shobhit Baijal, Aaron S. Mansfield, Chih‐Hsi S. Kuo, Kazumi Nishino, Se‐Hoon Lee, David Planchard, Christina S. Baik, Martha Li, Peter Ansell, Summer Xia, Ellen Bolotin, Jim Looman, Christine K. Ratajczak, Shun Lü - Journal of Clinical Oncology 2024 cited by 135

  21. Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

    Authors: Jang Ho Cho, Sung Hee Lim, Ho Jung An, Ki Hwan Kim, Keon Uk Park, Eun Joo Kang, Yoon Hee Choi, Mi Sun Ahn, Myung Hee Lee, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn - Journal of Clinical Oncology 2019 cited by 359

  22. Synthetic lethality-mediated precision oncology via the tumor transcriptome

    Authors: Joo Sang Lee, Nishanth Ulhas Nair, Gal Dinstag, Lesley M. Chapman, Youngmin Chung, Kun Wang, Sanju Sinha, Hongui Cha, Dasol Kim, Alexander Schperberg, Ajay Srinivasan, Vladimir Lazar, Eitan Rubin, Sohyun Hwang, Raanan Berger, Tuvik Beker, Ze’ev A. Ronai, Sridhar Hannenhalli, Mark R. Gilbert, Razelle Kurzrock, Se‐Hoon Lee, Kenneth Aldape, Eytan Ruppin - Cell 2021 cited by 162

  23. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study

    Authors: Caicun Zhou, Sang-We Kim, Thanyanan Reungwetwattana, Jianying Zhou, Yiping Zhang, Jianxing He, Jin-Ji Yang, Ying Cheng, Se‐Hoon Lee, Lilian Bu, Tingting Xu, Li Yang, Chao Wang, Ting Liu, Peter N. Morcos, You Lu, Li Zhang - The Lancet Respiratory Medicine 2019 cited by 272

  24. Regulatory (FoxP3+) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer

    Authors: Jiae Koh, Joon Young Hur, Kyoung Young Lee, Mi Soon Kim, Jae Yeong Heo, Bo Mi Ku, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn - Scientific Reports 2020 cited by 87